# Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

> **NCT03923556** · PHASE4 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 84 (actual)

## Conditions studied

- Kidney Transplant; Complications
- Postoperative Residual Curarization
- Postoperative Residual Weakness

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT03923556
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-02
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03923556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03923556, "Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03923556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*